Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.

PMID:30794215
Agarwal MG , Gundavda MK , Gupta R , Reddy R
Clinical orthopaedics and related research
Although giant cell tumors (GCTs) are benign, their aggressiveness and tendency to recur locally challenge the orthopaedic surgeon's ability to perform joint-preserving intralesional surgery with an acceptably low risk of local recurrence. Denosumab has emerged as a possible medical treatment of GCT because it seems to halt the progression of GCT, alleviate pain, and increase perilesional bone formation, but its exact role has been questioned, and specifically its efficacy and associated complications are not well characterized.


Copyright(C) 2006 BIOIMPACT Co., Ltd. All Rights Reserved